T cell vaccination in multiple sclerosis: results of a preliminary study.
Myelin basic protein (MBP)-reactive T cells are potentially involved in the pathogenesis of multiple sclerosis (MS), and can be depleted by subcutaneous inoculations with irradiated autologous MBP-reactive T cells (T cell vaccination). This preliminary open label study was undertaken to evaluate whether depletion of MBP-reactive T cells would be clinically beneficial to patients with MS. Fifty-four patients with relapsing-remitting (RR) MS (n=28) or secondary progressive (SP) MS (n=26) were immunized with irradiated autologous MBP-reactive T cells and monitored for changes in rate of relapse, expanded disability scale score (EDSS) and MRI lesion activity over a period of 24 months. Depletion of MBP-reactive T cells correlated with a reduction (40%) in rate of relapse in RR-MS patients as compared with the pre-treatment rate in the same cohort. However, the reduction in EDSS was minimal in RR-MS patients while the EDSS was slightly increased in SP-MS patients over a period of 24 months. Serial semi-quantitative MRI examinations suggest stabilization in lesion activity as compared with baseline MRI. The findings suggest some potential clinical benefit of T cell vaccination in MS and encourage further investigations to evaluate the treatment efficacy of T cell vaccination in controlled trials.
Zhang
Jingwu Z
JZ
Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Rivera
Victor M
VM
Tejada-Simon
Maria V
MV
Yang
Deye
D
Hong
Jian
J
Li
Sufanfg
S
Haykal
Hani
H
Killian
James
J
Zang
Ying C Q
YC
D019264:Adoptive Transfer / Q000379:methods*; D000328:Adult; D001921:Brain / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000276:immunology*; D010865:Pilot Projects; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*
D004676:Myelin Basic Protein